Model links tirzepatide's glucose edge to liver glucose suppression

A mechanistic longitudinal model built from 28-week trial data in patients with type 2 diabetes analyzed fasting glucose, insulin, insulin sensitivity, and beta-cell function to compare tirzepatide 15 mg and semaglutide 1 mg. The model reported that tirzepatide's superior fasting glucose control was driven mainly by greater insulin-independent suppression of hepatic glucose production, with beta-cell function initially rising then declining as insulin sensitivity improved. Simulations indicated low responders had deficient hepatic glucose suppression, and that enhancing this suppression improved fasting glucose without added beta-cell stress, whereas simulated increases in weight loss sped early improvement but did not further lower long-term fasting glucose.

Most relevant for: Patients with type 2 diabetes being treated with GIP/GLP-1 or GLP-1 receptor agonists, including those with suboptimal glycemic response.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.